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Supplementary Materials and Methods 
 
Cell lines, reagents and cell culture 
Human melanoma cell lines (M series) were established from patient’s biopsies under UCLA 
IRB approval # 11–003254. Cells were cultured in RPMI 1640 with L-glutamine (Mediatech, Inc, 
Manassas, VA), 10% fetal bovine serum (Omega Scientific Tarzana, CA), and 1% penicillin, 
streptomycin and fungizone (Omega Scientific Tarzana, CA). Cultures were incubated in a 
water-saturated incubator at 37°C with 5% CO2. Cells were maintained and tested for 
mycoplasma as described before (1, 2). Cell lines were periodically authenticated to their early 
passages using GenePrint® 10 System (Promega, Madison, WI). Presence of mutations in the 
genes of interest was checked by OncoMap 3 or Iontrone, and was confirmed by PCR and 
Sanger sequencing as previously described (1, 2).  
Vemurafenib (NC0621949, Selleck Chemicals LLC), trametinib (NC0592237, Selleck Chemicals 
LLC), and JSH-23 (S7351, Selleck Chemicals LLC) were dissolved in DMSO at designated 
concentrations before applying to cell culture media. All cell lines were plated in T-75 plates at 
60% confluency and treated with vemurafenib at twice the 50% inhibition concentration (2 × IC50) 
of each cell line using their previously described IC50 (Table S1). The DNA-antibody conjugates 
were synthesized with previous protocols reported (3). The list of ssDNA and antibodies used in 
this work is shown in Tables S6 and S7.  
Phenotype tracking by flow cytometry. 
Cell suspensions were stained for flow cytometry with PE conjugated anti human NGFR 
antibody from Biolegend (San Diego, CA). All cells were then fixed with Fix-Perm buffer from BD 
Bioscience (San Jose, CA) and stained for intracellular FITC conjugated anti human Melan-A 
antibody from Santa Cruz (Dallas, TX). Isotypes for mouse IgG1k and mouse IgG1 respectively 
were used to enable correct gating and to confirm antibody specificity. Blue live-dead staining 
from Life technologies (Waltham, MA) was used to discriminate alive. 10000 alive events were 
collected for each sample. Flow cytometry analysis was conducted using LSR-II from BD 
Biosciences (San Jose, CA), and the data was analyzed using FlowJo software (Tree Star, Inc., 
San Carlos, CA). The hierarchical clustering from the 18 cell lines, was performed using the 
expression levels in flow cytometry, with complete linkage and Euclidean distance metric. 
Gating of NGFR and Mart1 for defining cell states are all based on the staining of isotype 
controls. 
MITF Reporter Cell Line 
The human Tyrosinase Promoter (TP) was subcloned from pLightSwitch Prom S700747 
(SwitchGear Genomics, Carlsbad, CA), which was first digested with MluI (New England 
Biolabs; Ipswich, MA). Blunt ends were generated using T4 Polymerase (New England Biolabs) 
and the resulting fragment was digested again with Bgl II (New England Biolabs). Resulting 
1057 bp Tyrosinase promoter insert was then cloned by standard methods (4) into the BamH1 
and HpaI sites of the lentiviral vector backbone Lenti-D-EN-fLUC, driving the expression of the 
firefly luciferase gene.  
Lentivirus particles were generated as previously described (5) to stably transduce M229, M263 
and M397. Generated stable reporter cell lines M229TP, M263TP and M397TP from different 
conditions were trypsinized and seeded at a density of 100.000 cells per well in 96-well white-
bottomed plates. Luciferase activity was read out from white-bottomed plates using luciferin 
directly (1:10 Final dilution) and signal was normalized according to viability calculated using 
CellTiter-Glo (Promega, San Luis Obispo, CA) (1:2 final dilution), also plated in white-bottomed 
plates. Bioluminescence imaging was carried out with a Xenogen IVIS 200 Imaging System 
(Xenogen/Caliper Life Sciences). 
RNA-Seq 
RNA extraction was performed using AllPrep DNA/RNA Mini kit from Qiagen in 18 human 
melanoma cell lines samples and also in samples from M229, M263 and M397 treated under 
different conditions. Bioanalyzer confirmed correct integrity, library was constructed and Illumina 
50 bp single-end RNA-seq data was collected for the samples described. RNA sequencing was 
performed using 50 bps single end sequencing on the Illumina HiSeq 2500 platform. 
Libraries were prepared using the IlluminaTruSeq RNA sample preparation kit per 
the manufacturer’s instructions. Reads were mapped and aligned to the Homo sapiens NCBI 
build 37.2 reference genome using TopHat2 v2.0.9(6). Expression values in fragments per 
kilobase of exon per million fragments mapped (FPKM) were generated using Cufflinks v2.2.1 
program and Cuffnorm to quantify and normalize aligned reads using the geometric library size 
normalization method (7).  
The stochastic cell transition model 
The stochastic cell-state transition model is built by assuming a time-homogeneous Markov 
chain process as described in a previous publication (8). Two basic assumptions are made for 
the model: First, cells at four designated subpopulations transition randomly between states per 
certain unit time. Second, the transition probabilities depend only on a cell's current state, 
regardless of its prior states. The governing equations are listed below. 
  
Proportions of various states are listed as column vectors. The 4×4 state transition probability 
matrix with each element denoting the transition probability from one cell state to other states 
per unit time is pre-multiplied with a diagonal drug sensitivity matrix. The four diagonal elements 
of this matrix encode the relative viability of the two melanocyte, neural crest and double 
negative states in the presence of drug treatment. The calculated 4-element vector is 
normalized to have a summation of 1 to generate the new proportions vector. 
Kinetic flow cytometry data (Table S5) of segregated cell populations at different time points are 
used as input. Monte Carlo simulation is performed by random sampling differential transition 
probability and viability vectors to quantitatively infer the most probable values in the matrices 
that best recapitulate the experimental observations of sorted cells. The values inferred from 
sorted cells are then utilized to predict the cell state dynamics and final steady-state 
composition of unsorted cells under drug treatment (Fig. 2D). 
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Transcriptomic data analysis 
Heatmap and clustering analysis of transcriptomic dataset for all 9 cell lines was performed via 
MATLAB. Genes are pre-filtered by RPKM value with criteria of average value greater than1 
and coefficient of variance greater than 0.3. Filtered gene expression values were standardized 
across each row (normalized for each individual gene) and represented by redblue colormap. 
Hierarchical clustering was performed with average linkage and Euclidean distance metric. 
Whole transcriptomic dataset for each cell line upon drug treatment was also plotted as self-
organized mosaic maps with respective to its control via Gene Expression Dynamics Inspector 
(GEDI) (9). Each tile in the maps represents a minicluster of genes with similar expression 
kinetics. Gene clusters with related expression kinetics are placed close together, while clusters 
exhibiting very different kinetic trajectories are placed far apart. The tile color encodes the 
average expression level of the genes in that minicluster at a given time point. By extracting 
genes in interesting regions (e.g. common regions that are changing in the same direction 
across all cell line clusters or unique regions that are only changing in only one cluster, etc.), 
one could further investigate their biological functions. Genes in regions of interest are further 
enriched in the Gene Ontology Biology Process database using Enricher (10).  
For generating the phenotypic trajectory in Figs. 1D and S4, the MITF activity and neural crest 
signature scores were determined by using genes identified as MITF targets (11) and chicken 
embryo neural crest genes from Gallus EST in situ hybridization analysis – GEISHA- (12) (Table 
S3) respectively. Signatures scores were calculated by taking the sum of all log2 fold changes 
from DMSO control for all signature genes and divided by the square root of the total number of 
genes. 
Gene Set Enrichment Analysis (GSEA) was performed using GSEA v2.2.3 software with 1000 
permutations and weighted enrichment statistics. For correlation enrichment, we used Pearson 
correlation of relevant pathways with MITF, L1CAM, NGFR, NFκB1, CCL2, and AXL expression 
across patient samples. For the pre-ranked option with log2 fold changes were used as the 
ranking metric. Normalized enrichment score (NES) was assessed across the curated Molecular 
Signatures Database (MSigDB) Hallmark, C2 curated gene sets, and MITF signature (11). 
Using Database for Annotation, Visualization and Integrated Discovery (DAVID) 6.8, we looked 
at relevant Gene ontology (GO) terms for differentially expressed genes for M229, M263 and 
M397 at 21 days and 73-90 days of drug treatment with respect to DMSO control (Fig. S7).  
Microchip fabrication and single cell proteomic assay 
The fabrication of the SCBC devices and the protocol of the single cell proteomic assays were 
extensively discussed in our previous publications (13, 14). Briefly, the DNA microarrays at each 
microchamber were converted to antibody microarrays by flowing the DNA-antibody conjugate 
cocktail solution immediately prior to use. Cells were randomly loaded into the 310 
microchambers of the SCBC. Each microchamber has an assay component, and a separate 
reservoir of lysis buffer, and was photographed after cell loading. The SCBC was then cooled 
on ice for cell lysis. Following a 2-hour protein capture period at room temperature, the 
microchambers were flushed and the antibody arrays were developed using a cocktail of 
detection antibodies. The developed antibody barcode arrays were digitized by a Genepix 
scanner. Each array is matched with the micrograph of that array for preparing a table that 
contains the microchamber address, the numbers of cells, and the measured fluorescence 
levels of each assayed protein. 
Clonogenic assay 
Clonogenic assays were performed by plating melanoma cells in six-well plates with fresh 
media at an optimal confluence. The media (with drug or DMSO) were replenished every 
2 days. Upon the time of staining, 4% paraformaldehyde was applied onto colonies to fix the 
cells and 0.05% crystal violet solution was used for staining the colonies.  
Drug dose-response SRB assay 
The 3 cell lines were pre-seeded into 96-well plates for 48 hours before the addition of drug. 
After that, cells were treated with drug for 72 hours, and cell viability was determined using In 
Vitro Toxicology Assay Kit (TOX6, SIGMA-ALDRICH) following the manufacturer's instruction. A 
Bliss independence model was used to evaluate the effect of drug combination (15).  
Statistical analysis of SCBC data 
The SCBC readouts from the microchambers with a single cell were collected to form a data 
table. Each row of the table corresponds to a measurement of a panel of functional proteins 
from a single cell and each column contains digitized fluorescence intensities that provide 
readout of the levels of each of the assayed proteins. Protein-protein Spearman’s rank 
correlation coefficients can be directly calculated from single cell data. Protein correlation 
networks were generated by running the calculation through all the protein pairs in panel (Fig. 
S12). Bonferroni corrected p-value was used to define the statistical significance level for the 
entire panel and only those significant correlations were shown in the networks.  
The t-SNE dimensionality reduction analysis was performed on SCBC dataset following a 
previous published algorithm (16).  
A normalized PCA was used to peel off layer after layer of systematic co-variations from the 
data, in terms of principal components (PCs). The correlations between functional protein levels 
and PCs were calculated to quantify the dominative protein pattern of the signaling network 
coordination and its response to external perturbations such as drug treatment. The signaling 
network activity index (SNAI) is a metric of the overall strength of the protein signaling 
coordination at a given condition, and is defined as the reciprocal of the determinant of the 
protein-protein correlations. 
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Supplementary Figures 
 
Fig. S1. Phenotypic clustering of 18 BRAFV600 mutant melanoma cell lines upon BRAF 
inhibition. (A) Clustering of 18 cell lines based upon their partition percentages (color coded in 
red) in four phenotypic quadrants (inset) at baseline and upon BRAFi response identifies 4 
groups. The quadrants are defined by the gate setting of NGFR and MART-1 expression levels 
for each cell line in the flow cytometry analysis. Cluster C cells show highest phenotypic 
plasticity upon BRAF inhibition. Hierarchical clustering is performed with complete linkage and 
Euclidean distance metric (ST: 3 days vemurafenib treatment, LT: 3 weeks vemurafenib 
treatment). (B) Heat map of the genome-wide expression levels of 9 cell lines randomly selected 
from each cluster at control, 3 days, and 3 weeks vemurafenib treatment. Clustering is 
performed with average linkage by Euclidean distance metric. Four clusters are identified to be 
wholly consistent with the clustering results using MART-1 and NGFR markers in panel A. The 
clusters are labeled in lower case font, indicating that these cells represent a subset of those 
analyzed in panel A.  Up-regulated genes are colored in red and down-regulated genes in blue.
  
 
 
 
Fig. S2. Flow cytometry analysis of NGFR and MART-1 expression levels for 18 BRAFV600 
mutant melanoma cell lines treated with DMSO control and vemurafenib for 3 days and 
21 days. The average NGFR and MART-1 levels across treatment conditions are as bar graphs 
on the right (mean ± SEM). The cell lines are ordered according to the their respective clusters 
identified in Fig. S1A. 
 
 
Fig. S3. Enrichment analysis of commonly down-reglated genes across all the cell line 
clusters and uniquely up-regulated genes in cluster C upon BRAFi exposure. (A) GEDI 
visualization of differentially expression genes relative to control for all the cell line clusters upon 
21 days of vemurafenib treatment. Gene miniclusters circled in blue denote commonly down-
regulated genes across all the cell line clusters at varying degrees. Gene miniclusters circled in 
red denote genes that are uniquely up-regulated in Cluster C cells. (B and C) Gene Ontology 
enrichment using Enricher for genes circled in blue (or red). The top 10 ontology terms with 
highest enrichment scores are listed from top to buttom with decreasing p values.  
Fig. S4. Plot of MITF activity signature scores vs neuron differentiation (Molecular 
Signatures Database C5 Collection) signature scores for the 3 plastic cell lines across 
different time points upon vemurafenib treatment. Counterclockwise trajectories appear for 
all three lines (VC: DMSO control). 
 
 
Fig. S5. Cell growth kinetics of M397, M229 and M263 under DMSO control or BRAFi 
treatment overlaid with phenotypic profiles (M397 only). BRAFi exposure moderately 
inhibited the cell growth for a short-term followed by a drug tolerant exponential growth phase 
characteristic of the adaptive resistance to BRAFi (data are shown as mean ± SD) 
 
Fig. S6. MITF activity analyzed using a bioluminescence tyrosinase promoter (TP) 
reporter system through different time points of vemurafenib for M229TP, M263TP and 
M397TP. Each condition is normalized for 100,000 cells and viability. Data is representative of 
duplicate wells, and representative of an experiment done in two independent experiments. 
Error bars are standard deviation of the two wells. Luciferase representative images are shown 
underneath. 
 
Fig. S7. Transcriptional signatures of three plastic cell lines in Cluster C. (A) Heat map of 
expression levels for critical genes involved in the adaptive BRAFi resistance at baseline 
(DMSO) as well as upon 3 days, 21 days and 73-90 days of vemurafenib exposure. (B) Gene 
Ontology analysis of differentially expressed genes for the three plastic cell lines following 21 
days and 73-90 days drug treatment with respect to DMSO control. Relevant GO terms are 
listed with respective p-values, analyzed by DAVID. Blue terms denote GO term enrichment for 
down-regulated genes and red terms denote GO term enrichment for up-regulated genes. 
 
Fig. S8. GSEA shows enrichment of curated gene sets associated with the cell state 
regression towards neural-crest like and mesenchymal-like states upon 21 days 
vemurafenib exposure in other cell line clusters (NOM p values: *p<0.05; **p<0.005, 
***p<0.0005).  
 
Fig. S9. Transcriptional signatures of the cell state transition associated with the 
adaptive resistance in melanoma patient biopsies (transcriptomes from ref. 16 in the 
main text). (A) Heat map of GSEA normalized enrichment scores (NES) of relevant curated 
gene sets involved in the adaptive transition for 11 paired pre-treatment and on-treatment 
patient biopsies. More than half of patient samples show acquisition of neural crest-like and 
mesenchymal phenotype signatures with up-regulated NFκB and JNK signaling as identified in 
the cell line studies. (B) Correlation of critical regulatory genes with relevant transcriptional 
signatures associated with the adaptive resistance across 39 melanoma patient biopsy samples. 
Genes involved in the ECM reprogramming, focal adhesion, collagen formation, stemness, EMT 
signatures were negatively correlated with MITF and positively correlated with NGFR, NFκB, 
CCL2 and AXL. Gray shadow denotes an insignificant enrichment with a p value > 0.05. (C) 
Gene expression levels of patient samples at baseline (pre-treatment), on-treatment and 
resistant stages for three curated gene sets for invasiveness, stem cell and mesenchymal 
transition signatures. It revealed that the genes involved in cellular invasiveness, stem cell 
signature and EMT were consistently up-regulated at on-treatment stage and descending at 
acquired resistant stage, implying the existence of cellular regression towards neural crest-like 
and mesenchymal-like phenotypes as a non-genomic adaptive response in these on-treatment 
patient biopsies prior to the disappearance of these signatures when cells acquired robust 
therapy resistance potentially genetically.   
Fig. S10. The Markov model prediction and the experimental validation of cell state 
kinetics for segregated M229 and M397 cells. (A) Experimental flow for sorting cells to obtain 
NGFR+ and NGFR- subpopulations, and culturing each subpopulation in fresh growth media 
with or without BRAFi treatment. (B) For both M397 and M229 cell lines, unsorted cells or sorted 
NGFR+ or NGFR- subpopulations are cultured with or without drug, and their phenotype 
composition are monitored using flow cytometry until they reach to an equilibrium composition. 
The final equilibrium composition from unsorted, NGFR+/- subpopulations and model prediction 
are presented as bargraphs. DN – double negative mesenchymal-like state (NGFR-/MART-1-), 
NC – neural crest-like state (NGFR+/MART-1-), DP – double positive plastic state 
(NGFR+/MART-1+), melanocytic state (NGFR-/MART-1+).  
Fig. S11 Experiments setting and flow cytometry plots of sorted M397 NGFR+ and NGFR- 
subpopulations under treatment naïve and drug treatment conditions. Time-series flow 
cytometry phenotyping of M397 sorted subpopulations cultured without BRAFi (A) and with 
BRAFi (B) treatment. The cell cycle for M397 is 3 days. 
 
 
Fig. S12. Experiments setting and flow cytometry plots of sorted M229 NGFR+ and NGFR- 
subpopulations under treatment naïve and drug treatment conditions. Time-series flow 
cytometry phenotyping of M229 sorted subpopulations cultured without BRAFi (A) and with 
BRAFi (B) treatment. The cell cycle for M229 is 1 day. 
 
Fig. S13. Markov model of stochastic cell state transition predicts phenotypic evolution 
of melanoma cells upon BRAF inhibition. (A) Cell state transition probabilities of M229 at 
untreated and vemurafenib treated conditions. (B) Treatment sensitivity of different phenotypes 
for M229 inferred by the model. (C) Model prediction of the phenotypic kinetics (solid lines) 
versus experimental data (dots connected with dash lines) for M229 with continuous exposure 
to vemurafenib. (D) Model prediction of the phenotypic kinetics (solid lines) versus experimental 
data (dots connected with dash lines) for M397 and M229 when only drug selection is 
considered.  
 
 
Fig. S14. Reversibility of the adaptive transition upon drug removal (A) Phenotypic 
reversibility for the plastic M397 cell line in Cluster C and less plastic M233 cell line in Cluster B. 
While starting at different baseline phenotypic composition, both M397 and M233 cell lines 
follow the transition trajectory towards double negative state (NGFR-/MART-1-) upon drug 
exposure and return to their original composition upon drug removal. DR: drug removal. (B) The 
IC50 values for M397 cells at untreated, upon long-term drug exposure (46 days), and after 
long-term drug removal (treatment discontinued for 33 days), confirming the reverted cells are 
re-sensitized to BRAF inhibition.  
 
Fig. S15. The optical pictures of SCBC and its microchamber units: valves for chamber 
formation (red), valves for lysis buffer control (green), cell chamber compartment (blue), and 
lysis buffer reservoir (yellow) are delineated by food dyes. The sandwich immunofluorescence 
detection scheme with a scanned image is listed below the optical images. In the scanned 
image, the green stripes are used as alignment markers of a microchamber; each red stripe 
represents a functional protein measured and the fluorescence signal denotes the protein level 
from the single cells. 
 
Fig. S16. Protein-protein correlation networks of M397 cells at different time points, 
extracted from SCBC data. The correlation (orange) / anti-correlation (blue) strength were 
reflected in the thickness of the edges (see keys). 
 
Fig. S17. Immunofluorescence and flow cytometry analyses of NGFR and MART-1 
markers to BRAF inhibition. (A) Fold change of NGFR and MART-1 levels for mono- and 
combination therapies (23 days treatment) with respect to DMSO control on bulk M397 and 
M229 populations quantified by sandwich immunofluorescence assay. The predicted effective 
combinations (V+J and V+T+J) keep the MART-1 and NGFR levels unchanged, while V or V+T 
induces significant NGFR up-regulation and loss of MART-1 (error bars: ±SD). (B) Cell 
phenotype marker histograms from flow cytometry analysis of MART-1 and NGFR levels for 
mono- and combination therapies on both M397 (23 days drug treatment) and M229 (28 days 
drug treatment). 
 
Fig. S18. Synergy effects of combining vemurafenib (V) and trametinib (T) with JSH-23 (J). 
Percentage of excess activity over that expected under the Bliss independence assumption for 
each of the various dose combinations. Red indicates synergy; blue indicates antagonism. The 
red boxes outline the concentration ranges used in the long-term clonogenic assays in Fig. 4. 
*p<0.05 under Student's t-test. 
Fig. S19. Clonogenic assays for long-term combination therapy and short-term 
monotherapies in a cohort of melanoma cell lines. (A) Clonogenic assays of long-term drug 
treated samples were quantified using ImageJ software and normalized to V+T. The statistical 
significance is evaluated by Student's t-test. **p<0.005, ***p<0.0005. Error bars: ±SD). (B) The 
same doses used in long-term combination treatments were used for monotherapies here. No 
significant toxicity to the cells was observed for using JSH-23 alone (treatment time: M263, 7 
days; M229: 11 days; M308: 10 days; M249: 7 days).    
Fig. S20. Change in signaling coordination quantified as correlations between key 
functional proteins and the first principal component for control, day-6 (initiation of the 
adaptive transition), and day-23 (establishment of adaptive resistance). The up-regulation 
of JNK and p38α signaling axes is identified when the cells develop adaptive resistance to 
BRAFi. 
Supplementary Tables 
Table S1. Characterization of 18 melanoma cell lines used in this study, where 9 
randomly selected cell lines from each cluster for transcriptomic studies are shadowed 
in red. 
Cell line Sensitivity IC50 (nM) Mutational Status   
M370 R >10000 BRAFV600E mutant 
Cluster A M381 R >10000 BRAFV600E mutant 
M410 R 3510 BRAFV600E mutant 
M233 R >10000 
BRAFV600E mutant   
3 copies BRAF   
AKT1 amplification   
CCN31 amplification    
EGFR amplification   
CDKN2A deletion   
PTEN deletion 
Cluster B M238 S 243 
BRAFV600E mutant        
2 copies BRAF   
CDKN2A deletion    
PTEN deletion 
M255 I 1625 
BRAFV600E mutant    
2 copies BRAF   
AKT2 amplification   
CCND1 amplification   
EGFR amplification   
CDKN2A deletion 
M395 S 131 BRAFV600E mutant 
M406 S 645 BRAFV600E mutant 
M409 I 1018 BRAFV600E mutant 
M411 S 171 BRAFV600E mutant 
M229 S 282 
BRAFV600E mutant   
4 copies BRAF  
MITF amplification   
AKT1 amplification   
PTEN deletion 
Cluster C 
M263 I 839 
BRAFV600E mutant    
2 copies BRAF   
CDKN2A deletion 
M397 S 132 BRAFV600E mutant 
M399 I 1155 BRAFV600E mutant 
M403 S 450 BRAFV600E mutant 
M249 S 273 
BRAFV600E mutant   
3 copies BRAF    
MITF amplification   
AKT2 amplification  PTEN 
deletion Cluster D 
M262 S 150 
BRAFV600E mutant       
2 copies BRAF   
AKT1 mutation&amp   
CDKN2A deletion 
M308 R >10000 
BRAFV600E mutant   
3 copies BRAF   
MITF amplification   
AKT2 amplification   
EGFR amplification    
CDKN2A deletion 
 
Table S2. Color coded table comparing normalized median fluorescence intensity values 
for  MART-1 and NGFR upon 3 days and 21 days of vemurafenib exposure with respect to 
DMSO control. The data are extracted from flow cytometry analysis (Fig. S2) across 18 cell 
lines. Fold changes are listed and color coded (red: increase, blue: decrease). 
 
MART1 NGFR 
Cell lines Vem 3d Vem 21d Vem 3d Vem 21d 
M370 1.05 1.01 0.90 1.13 
M381 0.89 1.07 1.04 1.56 
M410 0.85 0.84 0.82 0.96 
M233 0.94 0.66 1.05 7.20 
M238 0.47 0.67 33.89 47.89 
M255 0.29 1.13 1.51 2.07 
M395 0.84 0.64 27.70 11.20 
M406 0.87 0.87 2.04 4.85 
M409 0.77 1.16 2.52 4.66 
M411 0.70 0.77 5.98 26.00 
M229 2.10 0.16 0.48 127.17 
M263 2.15 2.25 7.38 6.10 
M397 1.71 0.33 0.82 4.42 
M399 5.04 2.79 4.04 1.54 
M403 1.77 1.25 0.00 1.47 
M249 1.61 1.88 0.05 1.82 
M262 1.01 0.77 0.02 0.89 
M308 0.89 0.60 6.50 27.03 
 
 
Table S3. Complete chicken neural crest gene set list from Gallus Expression in situ 
Hybridization Analysis (GEISHA) (12) 
 
Chick_neural_crest	(GEISHA)
AARS HDAC2 PDGFD
ABCF2 HES1 PDGFRA
ACVR2B HES5 PEBP1
ADAM12 HES6 PENK
ADAM33 HEY1 PGK1
ADAMTS1 HEY2 PITX2
ADAMTS3 HK2 PLEKHG1
AGR2 HNRNPM POU3F4
AHCYL1 HOXA3 PTK7
ALK HOXB7 RAC1
ALX1 HS2ST1 RARA
ANGPTL4 HS3ST3A1 RARB
ANK3 HTRA1 RAR-GAMMA2
ANKRD6 ID2 RCC2
ANXA6 IPO9 RELT
AP2A2 IREB2 RERE
ARHGAP15 ISL1 RET
ARHGAP28 KDM4A RHOB
ASCL1 KIF4A RHOU
AUTS2 KLF10 RND3
B-G KTN1 ROBO1
BLNK LAMA5 ROBO2
BMP4 LECT1 RSPO3
BMP7 LFNG RXRA
BMPER LGR4 SALL4
BTBD11 LIMS1 SEMA3D
BTG2 LMNB2 SEMA7A
CADM3 LMO4 SIX1
CDH11 LOC100858038 SIX4
CDH6 LOC420041 SLC7A3
CRABP1 LZTS1 SLIT1
CXCL14 MAFA SMO
CXCR4 MAFB SNAI1
CYP26C1 MAFK SNAI2
DACH1 MAP3K5 SOX10
DACT2 MATN4 SOX2
DAD1 MCAM SOX8
DKC1 MECOM SOX9
DLL1 MEF2C SPRY2
DLL4 MKRN1 SREBF2
DLX3 MMP2 STOX1
DLX5 MOXD1 TBX1
DRGX MSX1 TBX3
DSC2 MSX2 TCF3
DSG2 MXI1 TFAP2A
EBF2 MYC TIAM1
EDNRB MYCN TIAM2
EFNB2 NCOA1 TIMP2
EGR4 NES TPD52L2
ELK3 NET1 TRIO
ENAH NEUROD4 TSHZ2
EPCAM NEUROG1 VSX1
ETS1 NHLH1 WIF1
EYA2 NKX2-5 WNT-1
FGF13 NOG WNT16
FGF3 NOLC1 WNT8A
FGFR2 NR6A1 ZEB2
FGFR3 NRP2 ZIC1
FLT4 OLFM1 ZRANB1
FOXD3 OSBP2
FRZB PALLD
FZD1 PAX3
GATA1 PAX7
GFRA2 PCDH15
GLG1 PCDH18
GTF2E2 PCDH8
Table S4. GSEA enrichment across innate anti-PD-1 resistance (IPRES) signature at 3 
days and 21 days of BRAFi exposure using averaged gene expression levels of the 3 
plastic cell lines. NES stands for normalized enrichment score. 
 
 
 
Table S5. Cell state composition measured by flow cytometry across time, while being with or without BRAF inhibition. DN 
– double negative mesenchymal-like state (NGFR-/MART-1-), NC – neural crest-like state (NGFR+/MART-1-), DP – double positive 
plastic state (NGFR+/MART-1+), melanocytic state (NGFR-/MART-1+).  
     NGFR+   NGFR-  
    Cycle DN NC Melanocytic DP Cycle DN NC Melanocytic DP 
M397 
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0 0.0% 2.4% 0.0% 97.6% 0 0.5% 0.0% 99.5% 0.0% 
1 0.3% 29.4% 0.7% 69.7% 1 3.3% 7.7% 32.1% 57.0% 
3 0.2% 28.1% 0.9% 70.8% 3 2.4% 22.0% 18.1% 57.5% 
6 0.3% 34.8% 2.9% 62.0% 6 3.3% 30.0% 17.7% 49.0% 
10 0.3% 34.0% 2.5% 63.2% 10 1.4% 26.9% 11.7% 60.0% 
15 0.4% 22.3% 3.8% 73.5% 15 2.9% 11.7% 31.7% 53.7% 
dr
ug
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0 0.0% 2.4% 0.0% 97.6% 0 0.5% 0.0% 99.5% 0.0% 
1 0.2% 9.1% 1.3% 89.6% 1 2.1% 2.9% 55.3% 39.7% 
3 0.1% 15.3% 1.7% 82.9% 3 1.6% 8.2% 33.0% 57.3% 
6 0.2% 30.1% 4.1% 64.0% 6 16.3% 14.9% 18.2% 50.6% 
10 30.1% 44.0% 3.8% 22.1% 10 50.7% 13.9% 19.4% 16.0% 
15 65.2% 27.7% 3.7% 3.4% 15 82.0% 11.9% 4.4% 1.7% 
                        
M229 
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 0 0% 59% 0% 41% 0 39% 0% 61% 0% 
7 20% 49% 19% 12% 7 34% 10% 55% 2% 
10 19% 46% 24% 12% 10 17% 12% 69% 2% 
15 38% 37% 20% 6% 15 28% 12% 58% 1% 
20 29% 25% 40% 5%           
dr
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7 6% 68% 3% 23% 7 10% 27% 35% 28% 
16 2% 82% 1% 16% 16 5% 51% 8% 37% 
38 10% 83% 0% 6% 38 25% 69% 1% 5% 
60 17% 72% 3% 8% 60 32% 56% 2% 11% 
71 38% 61% 0% 1% 71 68% 26% 5% 1% 
Table S6. Phenotype proportion for M397 and M229 unsorted cells under drug treatment 
condition. 
 
Cell Line Cycle DN NC Melanocytic DP 
M
39
7 
0 0% 7% 17% 76% 
2.3 0% 9% 25% 66% 
7 1% 44% 8% 46% 
14.3 53% 39% 1% 7% 
20.6 64% 32% 0% 4% 
22 76% 20% 0% 4% 
26 74% 21% 5% 1% 
 
     
M
22
9 
0 6% 7% 76% 12% 
11 2% 28% 25% 46% 
21 2% 63% 2% 32% 
30 1% 62% 2% 34% 
38 3% 75% 1% 22% 
60 25% 59% 16% 0% 
71 42% 52% 5% 1% 
 
 
Table S7. The sequences of the oligonucleotides used in the protein immunoassays. All 
oligonucleotides were synthesized by Integrated DNA Technology (IDT) and purified via 
high performance liquid chromatography (HPLC). The DNA coding oligomers were pre-
tested for orthogonality to ensure that cross-hybridization between non-complementary oligomer 
strands was negligible (<1% in photon counts).  
 
DNA sequence used for pattering ssDNA microarray 
A 5'-AAAAAAAAAAAAAATCCTGGAGCTAAGTCCGTA-3' 
B 5'-AAAAAAAAAAAAAGCCTCATTGAATCATGCCTA-3' 
C 5'-AAAAAAAAAAAAAGCACTCGTCTACTATCGCTA-3' 
D 5'-AAAAAAAAAAAAAATGGTCGAGATGTCAGAGTA-3' 
E 5'-AAAAAAAAAAAAAATGTGAAGTGGCAGTATCTA-3' 
F 5'-AAAAAAAAAAAAAATCAGGTAAGGTTCACGGTA-3' 
G 5'-AAAAAAAAAAAAAGAGTAGCCTTCCCGAGCATT-3' 
H 5'-AAAAAAAAAAAAAATTGACCAAACTGCGGTGCG-3' 
I 5'-AAAAAAAAAAAAATGCCCTATTGTTGCGTCGGA-3' 
K 5'-AAAAAAAAAAAAATAATCTAATTCTGGTCGCGG-3' 
L 5'-AAAAAAAAAAAAAGTGATTAAGTCTGCTTCGGC-3' 
M 5'-AAAAAAAAAAAAAGTCGAGGATTCTGAACCTGT-3' 
N 5'-AAAAAAAAAAAAAGTCCTCGCTTCGTCTATGAG-3' 
 
Complementary ssDNA Sequence for antibody conjugation 
A' 5'NH3-AAAAAAAAAAAAATACGGACTTAGCTCCAGGAT-3' 
B' 5'NH3-AAAAAAAAAAAAATAGGCATGATTCAATGAGGC-3' 
C' 5'NH3-AAAAAAAAAAAAATAGCGATAGTAGACGAGTGC-3' 
D' 5'NH3-AAAAAAAAAAAAATACTCTGACATCTCGACCAT-3' 
E' 5'NH3-AAAAAAAAAAAAATAGATACTGCCACTTCACAT-3' 
F' 5'NH3-AAAAAAAAAAAAATACCGTGAACCTTACCTGAT-3' 
G' 5'NH3-AAAAAAAAAAAAAAATGCTCGGGAAGGCTACTC-3' 
H' 5'NH3-AAAAAAAAAAAAACGCACCGCAGTTTGGTCAAT-3' 
I' 5'NH3-AAAAAAAAAAAAATCCGACGCAACAATAGGGCA-3' 
J' 5'NH3-AAAAAAAAAAAAACCTGCTCGACAACTAGAAGA-3' 
K' 5'NH3-AAAAAAAAAAAAACCGCGACCAGAATTAGATTA-3' 
L' 5'NH3-AAAAAAAAAAAAAGCCGAAGCAGACTTAATCAC-3' 
M' 5'Cy3-AAAAAAAAAAAAAACAGGTTCAGAATCCTCGAC-3' 
N' 5'NH3-AAAAAAAAAAAAACTCATAGACGAAGCGAGGAC-3' 
 
Table S8. List of antibodies used for the SCBC multiplex protein assays.  
Antibody Manufacture 
 Human NGFR DuoSet R&D DY367 
 Human sTNF DuoSet R&D DY225 
 Human S100B Mab Mouse IgG2A R&D MAB1820 
 S100B Rabbit mAb Cell Signaling 9550 
 Melan-A Monoclonal  Sigma-Aldrich M6570 
 Human Melan-A/MART-1 Sheep IgG R&D AF8008 
 Human Phospho-JNK2 DuoSet R&D DYC2236 
 Human MITF Goat IgG R&D AF5769 
 MITF abcam ab80651 
 Human/Mouse/Rat Phospho-ERK1 R&D DYC1825 
 Human NFκB1 Mouse IgG R&D MAB2697 
 NFκB1 p105/p50 Cell Signaling 3035 
 Human/Mouse NFκB p65 Mouse IgG2B R&D MAB5078 
 Phospho-NFκB p65 Rabbit mAb Cell Signaling 4025 
 Phospho-IκB alpha (Ser32) ELISA Kit Cell Signaling 7343 
 Phospho-p38 alpha DuoSet R&D DYC869B 
 Slug (SNAI2) mouse IgG Sigma-Aldrich 
SAB1412527 
 Slug Rabbit mAb Cell Signaling 9585 
  
Dataset S1. Kinetic RNA-seq data of the 9 randomly selected melanoma cell lines. (See 
Excel file attached). 
 
 
 
